医学临床研究
  2025年7月11日 星期五           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2024, Vol. 41 Issue (9): 1343-1345    DOI: 10.3969/j.issn.1671-7171.2024.09.017
  论著 本期目录 | 过刊浏览 | 高级检索 |
吲达帕胺联合贝那普利治疗高血压合并心力衰竭的临床疗效及其对患者血管活性物质水平的影响
曹学增, 刘柯良
社旗县中医院,河南 社旗 473300
Clinical Efficacy of Indapamide Combined with Benazepril in the Treatment of Hypertension Complicated with Heart Failure and its Influence on the Level of Vasoactive Substances in Patients
CAO Xuezeng, LIU Keliang
Sheqi Hospital of Traditional Chinese Medicine, Sheqi Henan 473300
全文: PDF (2237 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)       背景资料
摘要 【目的】探讨吲达帕胺联合贝那普利治疗高血压合并心力衰竭的临床疗效及其对患者血管活性物质水平的影响。【方法】选择2020年3月至2022年1月本院收治的108例高血压合并心力衰竭患者,根据治疗方法不同将其分为观察组(吲达帕胺联合贝那普利治疗)和对照组(氢氯噻嗪联合贝那普利治疗),每组54例。比较两组临床疗效、血管活性物质[内皮素(ET)、一氧化氮(NO)、血管活性肽(Apelin)、降钙素基因相关肽(CGRP)]、心功能指标[左心室收缩末内径(LVESD)、左心室射血分数(LVEF)、氨基末端B型脑钠肽前体(NT-proBNP)、左心室舒张末内径(LVEDD)、6 min步行距离(6MWD)],比较两组不良反应发生情况。【结果】治疗后,观察组临床有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者血清CGRP、NO、Apelin水平均高于治疗前,ET低于治疗前,观察组血清CGRP、NO、Apelin水平高于对照组,ET低于对照组(P<0.05)。治疗后,两组LVEF、6MWD高于治疗前,LVESD、LVEDD、NT-proBNP低于治疗前,观察组LVEF、6MWD大于对照组,LVESD、LVEDD、NT-proBNP低于对照组(P<0.05)。观察组与对照组不良反应总发生率比较,差异无统计学意义(P>0.05)。【结论】吲达帕胺联合贝那普利治疗高血压合并心力衰竭的临床疗效较好,可改善患者心功能,调节血管活性物质的表达。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
曹学增
刘柯良
关键词 高血压/并发症心力衰竭/并发症吲达帕胺/药理学血管紧张素转换酶抑制药/药理学    
Abstract:【Objective】To investigate the clinical efficacy of indapamide combined with benazepril in the treatment of hypertension complicated with heart failure and its influence on the level of vasoactive substances. 【Methods】A total of 108 patients with hypertension complicated with heart failure admitted to our hospital from March 2018 to January 2020 were selected and divided into observation group (indapamide combined with benazepril) and control group (hydrochlorothiazide combined with benazepril) according to the treatment method, with 54 cases in each group. The clinical efficacy, vasoactive substances [endothelin (ET), nitric oxide (NO), vasoactive peptide (Apelin), calcitonin gene-related peptide (CGRP)], cardiac function indexes [left ventricular end systolic diameter (LVESD), left ventricular ejection fraction (LVEF), N-terminal pro brain natriuretic peptide (NT-proBNP), left ventricular end diastolic diameter (LVEDD), and 6-min walking distance (6MWD)] were compared between the two groups, and the occurrence of adverse reactions was compared between the two groups. 【Results】After treatment, the clinical effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of serum CGRP, no and Apelin in the two groups were higher than those before treatment, and ET was lower than that before treatment. The levels of serum CGRP, no and Apelin in the observation group were higher than those in the control group, and ET was lower than that in the control group (P<0.05). After treatment, LVEF and 6MWD in the two groups were higher than before treatment, LVESD, LVEDD and NT-proBNP were lower than before treatment, LVEF and 6MWD in the observation group were higher than those in the control group, LVESD, LVEDD and NT-proBNP were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).【Conclusion】Indapamide combined with benazepril has good clinical efficacy in the treatment of hypertension complicated with heart failure, which can improve cardiac function and regulate the expression of vasoactive substances.
Key wordsHypertension/CO    Heart Failure/CO    Indapamide/PD    Angiotensin-Converting Enzyme Inhibitors/PD
收稿日期: 2023-05-12     
中图分类号:  R  
引用本文:   
曹学增, 刘柯良. 吲达帕胺联合贝那普利治疗高血压合并心力衰竭的临床疗效及其对患者血管活性物质水平的影响[J]. 医学临床研究, 2024, 41(9): 1343-1345.
CAO Xuezeng, LIU Keliang. Clinical Efficacy of Indapamide Combined with Benazepril in the Treatment of Hypertension Complicated with Heart Failure and its Influence on the Level of Vasoactive Substances in Patients. JOURNAL OF CLINICAL RESEARCH, 2024, 41(9): 1343-1345.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.09.017     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I9/1343
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn